| First Author | Wang Y | Year | 2009 |
| Journal | Cancer Prev Res (Phila) | Volume | 2 |
| Issue | 12 | Pages | 1059-64 |
| PubMed ID | 19934342 | Mgi Jnum | J:309210 |
| Mgi Id | MGI:6756659 | Doi | 10.1158/1940-6207.CAPR-09-0221 |
| Citation | Wang Y, et al. (2009) Preventive effects of bexarotene and budesonide in a genetically engineered mouse model of small cell lung cancer. Cancer Prev Res (Phila) 2(12):1059-64 |
| abstractText | In the present study, we examined the effect of bexarotene (Targretin) and budesonide in the chemoprevention of small cell lung carcinoma using a lung-specific knockout model of Rb1 and p53. Upon treatment with bexarotene, tumor incidence, number, and load were significantly reduced (P < 0.05). Budesonide treatment trended to inhibition, but the effect was not statistically significant (P > 0.05). Immunohistochemical staining indicated that bexarotene treatment decreased cell proliferation and increased apoptosis in tumors. The Rb1/p53 gene-targeted mouse seems to be a valuable model for chemopreventive studies on human small cell lung cancer. Our results indicate that the retinoid X receptor agonist bexarotene may be a potent chemopreventive agent in this cancer type. |
